Patents by Inventor Jonathan D. Roth

Jonathan D. Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity
    Publication number: 20180305430
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: January 29, 2018
    Publication date: October 25, 2018
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekblad, Jonathan D. Roth
  • Engineered polypeptides having enhanced duration of action and reduced immunogenicity
    Patent number: 9879063
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: January 30, 2018
    Assignee: Aegerion Pharmaceuticals, Inc.
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekblad, Jonathan D. Roth
  • ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION AND REDUCED IMMUNOGENICITY
    Publication number: 20160207974
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: August 27, 2015
    Publication date: July 21, 2016
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekblad, Jonathan D. Roth
  • Methods of treating obesity with two different anti-obesity agents
    Patent number: 8394765
    Abstract: Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: March 12, 2013
    Assignees: Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Jonathan D. Roth, Christen M. Anderson, Alain D. Baron
  • Methods for treating obesity and obesity related diseases and disorders
    Publication number: 20090156474
    Abstract: Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
    Type: Application
    Filed: November 1, 2005
    Publication date: June 18, 2009
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Jonathan D. Roth, Christen M. Anderson, Alain D. Baron
  • Methods for Treating Obesity and Obesity Related and Disorders
    Publication number: 20080207512
    Abstract: Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
    Type: Application
    Filed: November 14, 2007
    Publication date: August 28, 2008
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Jonathan D. Roth, Christen M. Anderson, Alain D. Baron